Logo
x

Search

Subscribe Now

Myelodysplastic Syndromes

Genentech's Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes

Genentech's Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Sy...

  • July 21, 2021
BMS and Acceleron's Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes

BMS and Acceleron's Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes

  • February 17, 2021
Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA's Approval to MDS and CMML

Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA's Approval to MDS and CMML

  • July 20, 2020
Aprea's APR-246 Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndromes with a TP53 Mutation

Aprea's APR-246 Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndromes with a TP53 Mutation

  • January 30, 2020
Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

  • June 4, 2019
Geron Reports the US FDA Acceptance of NDA for Imetelstat to Treat Transfusion-Dependent Anemia in patients with Lower Risk Myelodysplastic Syndromes

    Geron Reports the US FDA Acceptance of NDA for Imetelstat to Treat Transfusion-Dependent Anemia in patients with Lower Risk Myelod...

    • August 21, 2023
    Servier Reports the US FDA Acceptance of sNDA and Granted Priority Review of Tibsovo (ivosidenib) for R/R Myelodysplastic Syndromes

      Servier Reports the US FDA Acceptance of sNDA and Granted Priority Review of Tibsovo (ivosidenib) for R/R Myelodysplastic Syndrome...

      • August 16, 2023
      Faron Highlighted Positive P-I/II Study (BEXMAB) Results of Bexmarilimab for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

        Faron Highlighted Positive P-I/II Study (BEXMAB) Results of Bexmarilimab for Relapsed/Refractory Acute Myeloid Leukemia and Myelod...

        • July 19, 2023
        Servier Presents Updated P-I Study Results of Tibsovo (ivosidenib) for IDH1-Mutated Relapsed/Refractory Myelodysplastic Syndromes at EHA 2023

          Servier Presents Updated P-I Study Results of Tibsovo (ivosidenib) for IDH1-Mutated Relapsed/Refractory Myelodysplastic Syndromes...

          • June 12, 2023
          BMS Reports the US FDA Acceptance of sBLA for Priority Review and EMA Validation of Application for Reblozyl (luspatercept-aamt) as 1L Treatment of Anemia

            BMS Reports the US FDA Acceptance of sBLA for Priority Review and EMA Validation of Application for Reblozyl (luspatercept-aamt) a...

            • May 1, 2023
            BMS Reports P-III (COMMANDS) Study Results of Reblozyl (luspatercept-aamt) for Myelodysplastic Syndromes

              BMS Reports P-III (COMMANDS) Study Results of Reblozyl (luspatercept-aamt) for Myelodysplastic Syndromes

              • October 31, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.